Your browser is no longer supported. Please, upgrade your browser.
Settings
ACER Acer Therapeutics Inc. daily Stock Chart
ACER [NASD]
Acer Therapeutics Inc.
Index- P/E- EPS (ttm)-2.08 Insider Own16.80% Shs Outstand10.37M Perf Week-4.14%
Market Cap32.69M Forward P/E- EPS next Y-1.63 Insider Trans12.76% Shs Float8.28M Perf Month16.81%
Income-21.10M PEG- EPS next Q-0.46 Inst Own39.30% Short Float6.06% Perf Quarter-19.65%
Sales- P/S- EPS this Y-17.20% Inst Trans-0.02% Short Ratio1.19 Perf Half Y32.38%
Book/sh1.08 P/B2.57 EPS next Y12.80% ROA-108.40% Target Price- Perf Year-17.01%
Cash/sh0.50 P/C5.54 EPS next 5Y- ROE-127.00% 52W Range1.08 - 7.25 Perf YTD-30.67%
Dividend- P/FCF- EPS past 5Y42.10% ROI- 52W High-61.66% Beta1.75
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low157.41% ATR0.18
Employees17 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)48.36 Volatility5.32% 6.99%
OptionableYes Debt/Eq0.00 EPS Q/Q49.10% Profit Margin- Rel Volume0.09 Prev Close2.75
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume419.91K Price2.78
Recom2.50 SMA20-3.29% SMA50-0.39% SMA200-13.06% Volume38,460 Change1.09%
Jun-26-19Reiterated H.C. Wainwright Buy $55 → $10
Jun-25-19Downgrade William Blair Outperform → Mkt Perform
Jun-25-19Downgrade Raymond James Outperform → Mkt Perform
May-23-19Initiated Wedbush Outperform
Feb-15-19Resumed Raymond James Outperform $40
Dec-20-18Initiated Needham Buy $48
Feb-26-18Initiated ROTH Capital Buy
Dec-20-17Initiated H.C. Wainwright Buy $50
Oct-15-20 09:30AM  
Oct-02-20 02:37PM  
Oct-01-20 07:04AM  
Sep-28-20 03:30PM  
Aug-31-20 05:00PM  
Aug-25-20 09:00AM  
Aug-13-20 04:01PM  
Aug-05-20 09:00AM  
Jul-28-20 11:09AM  
Jul-27-20 07:29PM  
Jul-09-20 03:55PM  
03:43PM  
Jul-08-20 04:01PM  
Jun-24-20 01:53PM  
May-29-20 12:44PM  
May-21-20 08:30AM  
May-14-20 04:01PM  
May-11-20 04:05PM  
Apr-30-20 04:01PM  
Mar-18-20 04:05PM  
04:05PM  
Feb-26-20 03:00AM  
Feb-25-20 03:00AM  
Feb-24-20 04:05PM  
Jan-28-20 06:16PM  
Jan-05-20 07:00AM  
Dec-23-19 03:59PM  
Dec-17-19 07:56AM  
Dec-16-19 04:05PM  
Dec-05-19 12:50PM  
Nov-13-19 04:05PM  
Oct-28-19 04:01PM  
Oct-07-19 07:05AM  
Sep-11-19 08:00PM  
Aug-30-19 03:00PM  
02:30PM  
01:02PM  
10:04AM  
08:59AM  
Aug-29-19 10:00PM  
03:18PM  
12:27PM  
12:23PM  
Aug-28-19 09:34PM  
06:46PM  
01:00PM  
10:02AM  
Aug-27-19 10:00AM  
08:30AM  
06:35AM  
Aug-26-19 08:00PM  
07:33PM  
06:14PM  
Aug-25-19 10:28AM  
Aug-24-19 06:55AM  
Aug-23-19 08:00PM  
08:00PM  
06:06PM  
05:37PM  
03:00PM  
10:46AM  
Aug-22-19 08:45PM  
01:00PM  
06:30AM  
Aug-21-19 09:44PM  
10:45AM  
Aug-20-19 05:35PM  
03:08PM  
06:23AM  
Aug-19-19 07:07PM  
10:44AM  
09:15AM  
06:10AM  
Aug-16-19 09:35PM  
03:00PM  
02:14PM  
10:39AM  
Aug-15-19 11:25PM  
08:23PM  
04:37PM  
Aug-14-19 10:38AM  
06:50AM  
Aug-13-19 07:30PM  
04:05PM  
Aug-12-19 06:35PM  
10:37AM  
10:15AM  
09:19AM  
06:30AM  
Aug-10-19 12:00AM  
Aug-09-19 03:00PM  
10:08AM  
Aug-08-19 09:56PM  
06:35AM  
Aug-07-19 09:40PM  
04:38PM  
10:07AM  
Aug-06-19 06:09PM  
04:51PM  
Aug-05-19 06:05PM  
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASELAGE STEVEDirectorJul 24Buy3.5045,000157,50063,905Jul 28 09:02 AM
Joseph DonaldChief Legal Officer and SecyJul 24Buy3.5014,28549,99814,285Jul 28 09:01 AM
DUNN JOHN MICHAELDirectorJul 24Buy3.5021,42874,99827,380Jul 28 09:01 AM
Schelling ChrisPresident & CEOJul 24Buy3.50142,857500,0001,892,857Jul 28 09:00 AM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.